News zum Sektor Gesundheit aus Indien

 

Philips India is expanding its premium personal care offerings, focusing on male grooming and mother/child care to meet growing consumer demand. The company is introducing global product lines and seeing robust growth in the premium segment, indicating a shift towards value-conscious consumers. This strategy aims to accelerate growth and enhance market presence....

India and Brazil are actively discussing the expansion of their preferential trade agreement, aiming to boost market access and foster collaboration in crucial sectors like pharmaceuticals and banking. The recent Trade Monitoring Mechanism meeting focused on strengthening bilateral trade and investment, with a goal to significantly increase current trade figures. Results will be reviewed by top officials soon....

American pharmaceutical giant Eli Lilly and Company is investing over $1 billion (approx Rs 8,900 crore) in India to establish new contract manufacturing facilities, including a significant hub in Hyderabad. This strategic move aims to bolster its global manufacturing and supply capabilities, leveraging India's skilled workforce to develop and produce medicines for critical ailments....

Eli Lilly and Co. plans to invest more than $1 billion in India over the next few years to build new contract manufacturing capabilities in the South Asian nation, underscoring the US drugmaker's push to bolster its global supply network....

Eli Lilly will invest over $1 billion in India to establish new contract manufacturing facilities and a manufacturing and quality hub in Hyderabad. This significant investment aims to strengthen global supply capabilities and leverage India's skilled talent pool for producing life-changing medicines, reinforcing Hyderabad's position as a healthcare innovation hub....

Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

US President Trump announced a 100% tariff on imported branded and patented pharmaceuticals starting October 2025, aiming to boost domestic manufacturing. Indian generic drug makers are largely unaffected initially, but concerns loom over potential tariff expansion to complex generics. Sun Pharma faces significant exposure due to its US branded portfolio....

Donald Trump announced 100% tariffs on imported branded or patented pharmaceutical products from October 1, 2025, unless companies build US manufacturing facilities. This policy primarily impacts European nations exporting high-value drugs, while India's generic exports may largely be shielded, though "branded generics" classification remains a concern....

Investors of Indian pharmaceutical companies are worried about the prospect of further escalation amid U.S. trade tensions....

India is closely monitoring the potential impact of the US's proposed tariffs of up to 100% on imported branded and patented pharmaceutical drugs, set to begin October 1. The relevant ministries are examining the matter, recognizing the US as India's largest pharma export market, accounting for approximately $10 billion in FY25....

Donald Trump's tariff move impacts Indian pharma stocks. Companies like Sun Pharma, Cipla, and Dr. Reddy's face potential declines. US represents a major market for Indian exports....

Insight with Haslinda Amin, a daily news program featuring in-depth, high-profile interviews and analysis to give viewers the complete picture on the stories that matter. The show features prominent leaders spanning the worlds of business, finance, politics and culture. (Source: Bloomberg)...

Pharmaceutical stocks, particularly Indian firms, plummeted following President Trump's announcement of 100% tariffs on imported branded medicines to the US. Companies like Sun Pharma, Biocon, and Zydus Lifesciences experienced significant declines....

Um den gesamten Artikel unter timesofindia.indiatimes.com zu lesen, klicken Sie bitte auf die Überschrift...

India's pharmaceutical market demonstrated robust growth, climbing 8.1% in August, fueled by chronic treatments like cardiac and anti-diabetic drugs. Respiratory and cancer medications also saw strong demand. GLP-1 therapies experienced a remarkable 97% surge, significantly boosting anti-diabetic sales....

Indian firms that make active pharmaceutical ingredients, or APIs, are gearing up to supply the basic ingredient that goes in making copies of Novo Nordisk A/S's weight-loss drugs that are losing patent protection next year in several large markets....

Um den gesamten Artikel unter timesofindia.indiatimes.com zu lesen, klicken Sie bitte auf die Überschrift...

US prosecutors have asked a judge to drop charges related to alleged fentanyl trafficking against an Indian pharmaceutical executive, citing insufficient evidence to move forward with the case....

US president wants to up pressure on Russia to end war in UkraineGood morning, and welcome to our rolling coverage of business, the financial markets and the world economy.Donald Trump has reportedly asked the EU to levy tariffs of up to 100% on India and China, in order to increase pressure on Russia to end its war in Ukraine.We're ready to go, ready to go right now, but we're only going to do this if our European partners step up with us.As the global leader in obesity and diabetes, Novo Nordisk delivers life-changing products for patients worldwide. But our markets are evolving, particularly in obesity, as it has become more competitive and consumer- driven. Our company must evolve as well.It is always difficult to see talented and valued colleagues go, but we are convinced that this is the right thing to do for the long-term success of Novo Nordisk. We need a shift in our mindset and approach so we can be faster and more agile. Our transformation plan is designed to deliver this.8am BST: Spain Ind...

India is emerging as a prominent medical tourism destination for NRIs, driven by significantly lower healthcare costs and expanding insurance coverage. Elective surgeries range from $2,000 to $15,000, while complex procedures cost between $20,000 and $40,000, coupled with affordable insurance options....